La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Sangamo Therapeutics Gestione
Gestione criteri di controllo 3/4
Sangamo Therapeutics' Il CEO è Sandy Macrae, nominato in Jun2016, e ha un mandato di 8.17 anni. la retribuzione annua totale è $ 2.39M, composta da 29.9% di stipendio e 70.1% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.18% delle azioni della società, per un valore di $ 328.43K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.1 anni e 4.8 anni.
Informazioni chiave
Sandy Macrae
Amministratore delegato
US$2.4m
Compenso totale
| Percentuale dello stipendio del CEO | 29.9% |
| Mandato del CEO | 8.3yrs |
| Proprietà del CEO | 0.2% |
| Durata media del management | 2.2yrs |
| Durata media del Consiglio di amministrazione | 4.8yrs |
Aggiornamenti recenti sulla gestione
Recent updates
There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price Jump
Aug 03
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
Jul 23Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop
Jun 19We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package
May 29This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year
May 14Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding
Mar 23Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%
Mar 16We're A Little Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Rate
Mar 09Improved Revenues Required Before Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Find Their Feet
Feb 02Here's Why We're A Bit Worried About Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation
Dec 04Is Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Worth US$0.9 Based On Its Intrinsic Value?
Sep 11Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates
Aug 15Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Low P/S
Aug 08Analysts Are More Bearish On Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Than They Used To Be
May 30Analysts Just Published A Bright New Outlook For Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO)
May 13Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky
Apr 11We Think Sangamo Therapeutics (NASDAQ:SGMO) Needs To Drive Business Growth Carefully
Dec 20Pfizer, Sangamo reopen recruitment for late-stage trial of hemophilia A gene therapy
Sep 22Here's Why We're Watching Sangamo Therapeutics' (NASDAQ:SGMO) Cash Burn Situation
Sep 18Sangamo Therapeutics: Strong Fabry Data Puts Them In The Lead
Aug 31Sangamo Therapeutics: Cheap, But Justifiably So
Aug 09Need To Know: Analysts Just Made A Substantial Cut To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Estimates
May 08Will Sangamo Therapeutics (NASDAQ:SGMO) Spend Its Cash Wisely?
Apr 11Sangamo Therapeutics: Lost In Transition From Lab To Clinic
Feb 24Is Sangamo Therapeutics (NASDAQ:SGMO) In A Good Position To Deliver On Growth Plans?
Jan 10Sangamo Therapeutics: Remaining Bullish Ahead ASH Data In December
Dec 03We're Interested To See How Sangamo Therapeutics (NASDAQ:SGMO) Uses Its Cash Hoard To Grow
Sep 22Sangamo Therapeutics: Finding An Opportunity To Reload
Aug 21Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$250m |
| Mar 31 2024 | n/a | n/a | -US$328m |
| Dec 31 2023 | US$2m | US$716k | -US$258m |
| Sep 30 2023 | n/a | n/a | -US$250m |
| Jun 30 2023 | n/a | n/a | -US$199m |
| Mar 31 2023 | n/a | n/a | -US$127m |
| Dec 31 2022 | US$5m | US$709k | -US$192m |
| Sep 30 2022 | n/a | n/a | -US$178m |
| Jun 30 2022 | n/a | n/a | -US$172m |
| Mar 31 2022 | n/a | n/a | -US$176m |
| Dec 31 2021 | US$5m | US$689k | -US$178m |
| Sep 30 2021 | n/a | n/a | -US$181m |
| Jun 30 2021 | n/a | n/a | -US$135m |
| Mar 31 2021 | n/a | n/a | -US$124m |
| Dec 31 2020 | US$4m | US$682k | -US$121m |
| Sep 30 2020 | n/a | n/a | -US$76m |
| Jun 30 2020 | n/a | n/a | -US$102m |
| Mar 31 2020 | n/a | n/a | -US$96m |
| Dec 31 2019 | US$4m | US$662k | -US$95m |
| Sep 30 2019 | n/a | n/a | -US$118m |
| Jun 30 2019 | n/a | n/a | -US$104m |
| Mar 31 2019 | n/a | n/a | -US$90m |
| Dec 31 2018 | US$4m | US$636k | -US$68m |
| Sep 30 2018 | n/a | n/a | -US$63m |
| Jun 30 2018 | n/a | n/a | -US$62m |
| Mar 31 2018 | n/a | n/a | -US$58m |
| Dec 31 2017 | US$2m | US$612k | -US$55m |
Compensazione vs Mercato: La retribuzione totale di Sandy ($USD 2.39M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 1.54M ).
Compensazione vs guadagni: La retribuzione di Sandy è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Sandy Macrae (61 yo)
8.3yrs
Mandato
US$2,392,272
Compensazione
Dr. Alexander D. Macrae, also known as Sandy, M.B., Ch B, Ph D., MRCP, serves as an Independent Non-Executive Director of 4D pharma plc since August 27, 2019.Dr. Macrae has been the Chief Executive Office...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 8.3yrs | US$2.39m | 0.19% $ 343.5k | |
| Senior VP | 5.3yrs | US$1.06m | 0.036% $ 64.7k | |
| Senior VP & Chief Development Officer | 5.7yrs | US$1.03m | 0.044% $ 78.8k | |
| Head of Research | less than a year | Nessun dato | 0.014% $ 25.1k | |
| Head of Technology | less than a year | Nessun dato | Nessun dato | |
| Head of Corporate Communications & Investor Relations Officer | no data | Nessun dato | Nessun dato | |
| Senior VP | 3.1yrs | Nessun dato | 0.041% $ 74.4k | |
| Head of Technical Operations | 1.3yrs | Nessun dato | Nessun dato | |
| Head of Business Development & Alliance Management | less than a year | Nessun dato | Nessun dato | |
| Scientist II - Discovery & Translational Research | no data | Nessun dato | Nessun dato | |
| Vice President of Investor Relations & Corporate Communications | no data | Nessun dato | Nessun dato |
2.2yrs
Durata media
55yo
Età media
Gestione esperta: Il team dirigenziale di SGMO è considerato esperto (durata media dell'incarico 2.1 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| CEO, President & Director | 8.3yrs | US$2.39m | 0.19% $ 343.5k | |
| Independent Chairwoman of the Board | 10.3yrs | US$99.28k | 0.030% $ 54.3k | |
| Independent Director | 8.3yrs | US$80.53k | 0.024% $ 43.0k | |
| Member of Scientific Advisory Board | 4.8yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 4.8yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 4.8yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 4.8yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 4.8yrs | Nessun dato | Nessun dato | |
| Independent Director | 6.3yrs | US$76.78k | 0.025% $ 45.2k | |
| Member of Scientific Advisory Board | 4.8yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 4.8yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 4.8yrs | Nessun dato | Nessun dato |
4.8yrs
Durata media
66.5yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di SGMO sono considerati esperti (durata media dell'incarico 4.8 anni).